US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Final data from the AGENT study confirms topline results

GOTHENBURG, Sweden, November 25, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that analysis of the AGENT study’s final data confirmed topline results presented on August 3, 2022. Moreover, no predictive gene expressions for clinical response could be identified. Isofol is continuing its efforts to terminate the AGENT study in line with applicable ethical and regulatory requirements, complete the final study report for submission to regulatory agencies and prepare a manuscript for a scientific publication. Isofol is in parallel continuing to investigate possible

Isofol Medical AB (publ) publishes interim report, January–June 2022

GOTHENBURG, Sweden, August 23, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January–June 2022 is now available on the company's website, www.isofolmedical.com.The information in the press release is intended for investors. Second quarter, April–June 2022 · Net revenue amounted to TSEK 4,027 (7,333) and other revenue to TSEK 0 (0) · The result for the period amounted to TSEK -54,033 (-45,394) · Earnings per share amounted to SEK -0.33 (-0.48) · Cash and cash equivalents at June 30 amounted to TSEK 277,727 (

Isofol Medical AB (publ) publishes interim report, January–March 2022

GOTHENBURG, Sweden, May 12, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January–March 2022 is now available on the company's website, www.isofolmedical.com .First quarter, January–March 2022 · Net revenue amounted to TSEK 4,006 (5,215) and other revenue to TSEK 1 (0) · The result for the period amounted to TSEK -47,874 (-42,662) · Earnings per share amounted to SEK -0.30 (-0.51) · Cash and cash equivalents on March 31 amounted to TSEK 332,035 (77,524)

Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study

GOTHENBURG, Sweden, January 15, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that a poster presentation is presented today at ASCO Gastrointestinal Cancers Symposium (ASCO-GI). The abstract present results from the Phase I/IIa ISO-CC-005 study which shows a correlation between clinical benefit and gene expression of the folate pathway in patients with metastatic colorectal cancer treated with 5-FU-based chemotherapy in combination with arfolitixorin. Furthermore, Isofol gives an update of the timing of the interim analysis in the

Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress

GOTHENBURG, Sweden, September 29, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced a poster presentation on the ongoing global Phase 3 AGENT clinical study in patients with metastatic colorectal cancer (mCRC). The poster will be presented at the 2019 European Society of Medical Oncology (ESMO ) Congress, which is being held from September 27 to October 1, 2019, in Barcelona, Spain.Details on the presentation are as follows: Title: Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-

Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from an open-label extension study for the ISO-CC-005 Phase 1/2a study of arfolitixorin in patients with metastatic colorectal cancer (mCRC). New results from 19 patients treated in the first-line setting showed early tumor shrinkage, defined as a greater than 20 % reduction in tumor size from baseline, in 47 % of patients (9/19) treated with the selected dose regimen, a combination of 120 mg/m² arfolitixorin and 5-fluorouracil (5-FU) with either irinotecan

First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer

GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first patient has been enrolled in the pivotal Phase 3 AGENT clinical study evaluating arfolitixorin for the treatment of metastatic colorectal cancer (mCRC). AGENT is a randomized, controlled, multi-centre study with blinded independent review of the tumour response.    AGENT (ISO-CC-007) will enrol approximately 440 mCRC patients, aged 18 years or over, to receive arfolitixorin or leucovorin, both in combination with 5-FU, oxaliplatin and bevacizumab. The primary

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe